Accolade (ACCD) Receives a Buy from Truist Financial

In a report released today, Jailendra Singh from Truist Financial maintained a Buy rating on Accolade (ACCD – Research Report), with a price target of $9.00. The company’s shares closed yesterday at $6.39.

Singh covers the Healthcare sector, focusing on stocks such as Icon, Evolent Health, and Phreesia. According to TipRanks, Singh has an average return of -15.6% and a 29.19% success rate on recommended stocks.

In addition to Truist Financial, Accolade also received a Buy from Stifel Nicolaus’s David Grossman in a report issued today. However, on the same day, Barclays maintained a Hold rating on Accolade (NASDAQ: ACCD).

The company has a one-year high of $15.36 and a one-year low of $5.88. Currently, Accolade has an average volume of 696.6K.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Accolade (ACCD) Company Description:

Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. it generates revenue through providing personalized health guidance solutions to members.